Gujarat Kidney & Super Speciality Ltd
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]
- Market Cap ₹ 1,059 Cr.
- Current Price ₹ 134
- High / Low ₹ 148 / 98.2
- Stock P/E 107
- Book Value ₹ 31.3
- Dividend Yield 0.00 %
- ROCE 9.34 %
- ROE 7.28 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.5% over last 3 years.
- Company has high debtors of 172 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE Healthcare BSE IPO Nifty IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 0.00 | 4.77 | 35.17 | 40.10 | |
| 0.01 | 3.20 | 19.73 | 23.95 | |
| Operating Profit | -0.01 | 1.57 | 15.44 | 16.15 |
| OPM % | 32.91% | 43.90% | 40.27% | |
| 0.00 | 0.70 | 0.11 | 0.49 | |
| Interest | 0.00 | 0.04 | 0.53 | 1.15 |
| Depreciation | 0.00 | 0.28 | 2.93 | 2.94 |
| Profit before tax | -0.01 | 1.95 | 12.09 | 12.55 |
| Tax % | 0.00% | 25.13% | 24.73% | 21.12% |
| -0.01 | 1.45 | 9.11 | 9.90 | |
| EPS in Rs | -0.50 | 72.50 | 1.60 | 1.26 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 897% |
| TTM: | 9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 12% |
| Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.20 | 0.20 | 11.37 | 15.77 |
| Reserves | 0.17 | 10.69 | 14.05 | 230.69 |
| 0.00 | 1.94 | 5.48 | 16.08 | |
| 3.50 | 3.99 | 18.17 | 3.54 | |
| Total Liabilities | 3.87 | 16.82 | 49.07 | 266.08 |
| 2.67 | 9.74 | 28.42 | 25.71 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.00 | 1.51 | 108.58 |
| 1.19 | 7.08 | 19.14 | 131.79 | |
| Total Assets | 3.87 | 16.82 | 49.07 | 266.08 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 0.00 | -2.11 | 15.36 | -7.46 | |
| 0.00 | -7.35 | -19.43 | -213.76 | |
| 0.00 | 10.63 | 4.80 | 226.94 | |
| Net Cash Flow | 0.00 | 1.17 | 0.73 | 5.72 |
| Free Cash Flow | 0.00 | -9.46 | -2.62 | -7.68 |
| CFO/OP | 0% | -100% | 115% | -22% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 318.32 | 132.84 | 171.85 | |
| Inventory Days | 317.90 | 66.36 | 65.73 | |
| Days Payable | 2,825.81 | 211.78 | 95.12 | |
| Cash Conversion Cycle | -2,189.58 | -12.57 | 142.46 | |
| Working Capital Days | 114.01 | -26.88 | 54.07 | |
| ROCE % | 19.55% | 57.72% | 9.34% |
Insights
In beta| Mar 2026 | |
|---|---|
| Acquired Ownership Stake - Ashwini Medical Centre % |
|
| Acquired Ownership Stake - Harmony Medicare Private Limited % |
|
| Acquired Ownership Stake - Parekhs Hospital Private Limited % |
|
| Acquired Ownership Stake - Patel Multispeciality Hospital and ICU % |
|
| Acquired Ownership Stake - Patel Pharmacy % |
|
| Acquisition Cost - Ashwini Medical Centre INR |
|
| Acquisition Cost - Harmony Medicare Private Limited INR |
|
| Acquisition Cost - Parekhs Hospital Private Limited INR |
|
| Acquisition Cost - Patel Multispeciality Hospital and ICU INR |
|
| Acquisition Cost - Patel Pharmacy INR |
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report for FY2025-26 notes Rs.10,000 fines each by BSE and NSE for delays.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 29 May
-
Announcement under Regulation 30 (LODR)-Change in Management
28 May - Board approved audited standalone and consolidated FY26 results; CEO appointment deferred; postal ballot for IPO-object variation.
-
Announcement under Regulation 30 (LODR)-Change in Management
28 May - Board approved FY26 audited standalone and consolidated results; CEO appointment deferred, postal ballot for IPO object variation.
-
Financial Results As On 31.03.2026
28 May - Board approved FY26 audited standalone/consolidated results, deferred CEO appointment, and planned postal ballot for IPO object variation.
Annual reports
No data available.
Business Profile[1]
Gujarat Kidney and Super Speciality Limited is a regional healthcare operator in central Gujarat, running a chain of mid-sized multi-speciality hospitals focused on secondary and tertiary care.